By attending this webinar you will discover statistical methodologies which will help rescue your trial from the challenges caused by the COVID-19 pandemic.
Estimands have become an increasingly hot topic for statisticians within our industry. The ICH E9 R1 addendum is entitled ‘Estimands and sensitivity analysis in clinical trials’ and is expected to be finalized in the coming months.
In this webinar, our presenters will provide guidance and support for those preparing a submission of their Investigational New Drug (IND) to regulatory bodies.
This white paper explores the use of Model-based Designs in Phase I Oncology Studies, providing advantages and explanation for the slow uptake of this design method.
This Whitepaper gives examples of how real-world data helps the development of gene therapies by considering the contribution of conducting adequate and controlled studies.
This Whitepaper focuses on designing and analyzing clinical trials for the treatment of Hemophilia A, exploring particularly the small population it effects, the slow recruitment rate and many other factors that should be considered.
In this whitepaper, we will provide you with key points on how to prevent your CDISC Define.xml code from common mistakes using assumptions in the stylesheet; and simple adjustments and more complex examples.
In this webinar we will examine the challenges of rare diseases studies focusing on gene therapy treatments, including appropriate study design, statistical analyses and long-term post-authorization pharmacovigilance and risk management requirements.
Within this white paper you will be introduced to Statistical Consultancy for clinical trials and the benefits it can provide. Advice may cover issues from study design and strategies, to the analysis of study data and informed interpretation of results.
This paper illustrates the benefits of a Pharmacokinetics (PK) Handover Document in PK Studies and how such documents should be customized, detailing, ideally, what kind of information should be contained to transfer PK data between statistics and programming departments.
This whitepaper introduces Statistical Monitoring and the creation of the Statistical Monitoring Report in response to a risk-based approach and the recent ICH GCP E6(R2) addendum.
This paper on 'Pharmacovigilance (PV) Literature Searches' explores optimizing search strategies for patient safety and presents the elements and requirements for a successful PV literature search strategy.
Within this whitepaper, we will look at some of the potential pitfalls with the production of SAS Macros and what makes a successful process improvement project. We will discuss approaches and solutions that we identified to typical problems.
This paper on 'Semi-Automated Patient Safety Narratives' explains what to do when a large volume of narratives is required within a restrictive time frame and details how a semi-automated approach to narrative writing can be used to address this challenge.
In this webinar, you will learn how implementation, evolution and change management are critical for a successful remote monitoring program. But how does a remote monitoring program harmonize with current Source Data Verification practices?
In today’s clinical trial environment you are likely to consider selecting an Electronic Data Capture (EDC) system, with few companies opting for paper based solutions. Yet with the rapid pace of technological advancement, it can prove increasingly difficult to identify the right electronic solution(s) for your study/development program.
This free webinar looks at the challenges of pharmacovigilance in early phase clinical trials. We demonstrate the importance of PV in early phase clinical trials and how it is not just a check box exercise to satisfy regulatory bodies
This paper describes current regulatory requirements with regards to patient safety narratives. It details a proposed process for their development and review and examines ways to lessen the burden of time and cost.
This paper reviews the different approaches to sourcing in clinical development. Quanticate is seeing a wide range of sourcing scenarios and this paper assesses these different strategies.
In this white paper, we focus on some of the key issues which should be considered when performing pharmacokinetic analyses to prove clinical comparability between innovator biologics and recently developed biosimilars.
This white paper looks at how the different perspectives to achieving efficiency in Clinical Programming can be achieved. This article explores balanced perspectives over narrow perspectives and how overall efficiencies and distinct efficiencies need to be separated.
As the choices for different clinical trial technologies grow, and the existing relationship between a sponsor and a CRO develops, the process of selecting a technology provider needs to examine a range of issues that didn't exist a few years ago.
SDTM standards do not always lead themselves well to data capture, this guide looks at using CDASH standards to provide a common ground to facilitate the capture of data when linking processes across clinical data management and clinical programming.
PKPD models are becoming increasingly critical knowledge-building tools, not only for late phase clinical trials but throughout the entire drug development process.
This paper looks at how a Medical Writer should contribute to the production of a quality ISS/ISE. It follows a previous white paper on the role of Statisticians and Programmers in the production of integrated summaries.
This article outlines the support needed from medical writers during the design, conduct and reporting of Phase I studies, but also their obligations when it comes to publishing results.
If you are planning an oncology study, you will be aware that these studies are more complex than others. Our consultancy team at Quanticate have put together an initial article that outlines the typical challenges presented by such studies and offers some recommendations to counter them.
This 14-page article looks at SAS® programming techniques to help you program more efficiently. Size reduction techniques for large datasets are explored to give you smaller sized, faster running, more efficient programs.
This 8-page article on Important Considerations for Clinical Development Programs is for anyone embarking on the development of a new medicinal product.
This article outlines the considerations that need to be made at the planning stage, and how to make best use of emerging PK and safety data to enable informed decisions regarding study progression.
If you are planning a Phase II study, you may find this 8-page article useful as it looks at how the Bayesian framework provides solutions for clinical development teams.
This second article expands on how the Bayesian framework is highly appropriate for planning and executing interim analyses in your clinical trial study design.
A 4-page article talks about a need to improve pharmacovigilance systems to more effectively monitor and take action on safety issues associated with medicines.
One of the most powerful aspects for ensuring a successful relationship, and a key part of the FSP model, is the governance between the sponsor and CRO
This case study presents a long-term Functional Service Provision with one of the top five pharmaceutical company across our biostatistics and clinical programming services.
Quanticate has been working successfully with a large Scandinavian pharmaceutical company over the past 12 months in the area of clinical data management (CDM) and is focused on the delivery of clean quality clinical trial databases.
This whitepaper introduces risk-based monitoring (RBM) and its four major components including Statistical Monitoring (SM) and the creation of the Statistical Monitoring Report (SMR).